You are viewing the site in preview mode

Skip to main content

Advertisement

Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

Fig. 1

Change in sum of target lesion diameters over time with avelumab in evaluable patients. a First-line switch-maintenance subgroup (n = 81). b Second-line subgroup (n = 52). Color coding is based on best overall response per Response Evaluation Criteria in Solid Tumors version 1.1. Dotted lines indicate the 3-month timepoint and changes in target lesion size of −30, 0, and +20%

Back to article page